ATTR Amyloidosis Treatments: Stabilizers and Silencers

Send us Fan MailIn this episode of All Things Amyloid, the focus is on the two primary treatments available for ATTR amyloidosis. Adapted from his video “ATTR Amyloidosis Treatments: Stabilizers and Silencers,” Dr. Brett Sperry, cardiologist and director of the Cardiac Amyloidosis Program at Saint Luke’s Mid America Heart Institute, provides an excellent overview of FDA-approved ATTR amyloidosis treatments. He goes into detail about the biology behind silencers and stabilizers and exactly how they impair amyloidosis progression. In addition, he previews the future, summarizing new categories of drugs on the horizon. The future is indeed exciting! (Update: In November, 2024 the FDA approved Attruby, and in March, 2025 the FDA approved Amvuttra.) For an overview of amyloidosis, please see episode 2 (for clinicians) or episode 3 (for patients).